Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Internal Medicine | Conference News

Back to Journal Articles

ESC: Otamixaban Effective in Acute Coronary Syndromes

Last Updated: August 31, 2009.

In patients with non-ST-elevation acute coronary syndromes, otamixaban may be more effective than standard treatment, according to a study published online Aug. 30 in The Lancet and presented at the European Society of Cardiology Congress 2009, held from Aug. 29 to Sept. 2 in Barcelona, Spain.

MONDAY, Aug. 31 (HealthDay News) -- In patients with non-ST-elevation acute coronary syndromes, otamixaban may be more effective than standard treatment, according to a study published online Aug. 30 in The Lancet and presented at the European Society of Cardiology Congress 2009, held from Aug. 29 to Sept. 2 in Barcelona, Spain.

Marc S. Sabatine, M.D., of Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues randomly assigned 3,241 patients to receive one of five doses of otamixaban or to a control of unfractionated heparin plus eptifibatide.

Compared to the control regimen, the researchers found that otamixaban doses of 0.105 or 0.140 mg/kg/h were associated with a 40 percent reduction in death or ischemic complications and had a similar safety profile. However, they found that doses lower than 0.070 mg/kg/h offered inadequate anticoagulation because they were associated with at least a two-fold increase in need for a bailout glycoprotein IIb/IIIa inhibitor and in thrombotic complications during percutaneous coronary intervention.

"Our study offers additional preliminary evidence for the efficacy and safety of direct factor Xa inhibition with otamixaban in patients with coronary disease," the authors conclude. "Examination of the ischemic, thrombotic, and bleeding event rates across the five doses tested provides a clear signal as to the optimum dose to be used in a large phase 3 trial of otamixaban in acute coronary syndromes."

The study was supported by Sanofi-Aventis; several authors reported financial relationships with Sanofi-Aventis.

Abstract
Full Text (subscription or payment may be required)
Comment (subscription or payment may be required)
More Information


Previous: Childhood Immunization Levels Remain Stable and High Next: Liver Fat, Not Visceral Fat, Linked to Obesity

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: